Phaseline

Targets › NAMPT

NAMPT (Nicotinamide phosphoribosyltransferase): drug programs, companies and trials

8 programs from 8 companies in 14 trials: 8 Phase 2, 4 Phase 1, 1 Phase 4, 1 Phase 3; Other, Oncology, Neurology; next expected readout Dec 2026.

Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack…. (UniProt, P43490)

Open in Phaseline: the race on NAMPT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of OklahomaNicotinamide riboside
NAD+ precursor; increases cellular NAD+ levels
NAMPTPhase 4AgingJun 2027
ORIC PharmaceuticalsRinzimetostat
NAMPT inhibitor
NAMPTPhase 3Metastatic Castration Resistant Prostate CancerMar 2028
University of Colorado, DenverNicotinamide Riboside
NAD+ precursor, vitamin B3 derivative that replenishes intracellular NAD+ pools
NAMPTPhase 2Vascular Diseases; Clonal Cytopenia of Undetermined SignificanceJul 2027
Haukeland University HospitalNicotinamide Riboside (NR)
NAD+ precursor; increases cellular NAD+ levels
NAMPTPhase 2Sleep; Multiple Sclerosis; Frailty; Progressive Supranuclear Palsy …Aug 2027
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauNicotinamide (NAM)
NAD+ precursor; promotes NAD+ biosynthesis and may support cellular metabolism and anti-in
PARP1, NAD1, NAMPTPhase 2Fatty LiverDec 2027
Metro International BiotechNicotinamide Mononucleotide (NMN)
NAD+ precursor; substrate for nicotinamide phosphoribosyltransferase (NAMPT)
NAMPTPhase 1Healthy AdultsDec 2026
The University of Texas Health Science Center, HoustonNicotinamide riboside (NR)
NAD+ precursor; increases cellular NAD+ levels through the salvage pathway
NAMPTPhase 1Smooth Muscle Dysfunction Syndrome (SMDS)Jul 2027
Remedy PlanRPT1G
Selective hyperbolic NAMPT inhibitor
NAMPTPhase 1Acute Myeloid LeukemiaDec 2028

Conditions

Healthy Adults (2) Sleep (1) Multiple Sclerosis (1) Frailty (1) Progressive Supranuclear Palsy (1) Alzheimer Disease (AD) (1) Vascular Diseases (1) Clonal Cytopenia of Undetermined Significance (1) Aging (1) Metastatic Castration Resistant Prostate Cancer (1) Fatty Liver (1) Smooth Muscle Dysfunction Syndrome (SMDS) (1)

Modalities

small molecule (6), mixed (1)

Companies

Haukeland University Hospital (1) University of Colorado, Denver (1) University of Oklahoma (1) ORIC Pharmaceuticals (1) Metro International Biotech (1) Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) The University of Texas Health Science Center, Houston (1) Remedy Plan (1)

Related targets

PARP1 (1) NAD1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.